Catalyst Receives IND Approval from S. Korea

Catalyst Biosciences has received IND approval from South Korea for a Phase I/II clinical study of their subcutaneous recombinant factor IX candidate CB 2679d/ISU304.  The product is a factor IX variant that was developed by making thousands of mutated factor IX molecules and then screening them to identify ones that had desirable properties.  Catalyst plans to start their clinical study by mid-2017.